Skip to main content

TP-0903-102 A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Tolero Pharmaceuticals, Inc

Start Date

January 10, 2019

End Date

September 17, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Tolero Pharmaceuticals, Inc

Start Date

January 10, 2019

End Date

September 17, 2020